Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2019 Oct 11;10:1172. doi: 10.3389/fphar.2019.01172

Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases

Dhani Raj Chhetri 1,*
PMCID: PMC6798087  PMID: 31680956

Abstract

Myo-inositol has been established as an important growth-promoting factor of mammalian cells and animals. The role of myo-inositol as a lipotropic factor has been proven, in addition to its involvement as co-factors of enzymes and as messenger molecules in signal transduction. Myo-inositol deficiency leads to intestinal lipodystrophy in animals and “inositol-less death” in some fungi. Of late, diverse uses of myo-inositol and its derivatives have been discovered in medicinal research. These compounds are used in the treatment of a variety of ailments from diabetes to cancer, and continued research in this direction promises a new future in therapeutics. In different diseases, inositols implement different strategies for therapeutic actions such as tissue specific increase or decrease in inositol products, production of inositol phosphoglycans (IPGs), conversion of myo-inositol (MI) to D-chiro-inositol (DCI), modulation of signal transduction, regulation of reactive oxygen species (ROS) production, etc. Though inositol pharmacology is a relatively lesser-known field, recent years of research has generated a critical mass of information on the subject. This review aims to summarize our current understanding on the role of inositol derivatives in ameliorating the symptoms of different diseases.

Keywords: myo-inositol, phospholipid, cyclitol, phytic acid, lipodystrophy, D-chiro-inositol

Introduction

Inositols are polyols having six-carbon ring structure where each carbon is hydroxylated. A number of these sugar-alcohol isomers are biologically active, of which myo-inositol (MI) is the most common (Majumdar et al., 1997). It constitutes a component of membrane phospholipids and mediates osmoregulation (Majumder and Biswas, 2006). Its phosphorylated derivatives act as second messengers in signal transduction pathways (Berridge, 2009), mediate phosphorylation of proteins (Saiardi et al., 2004), participate in chromatin remodeling and gene expression (Odom et al., 2000; Shen et al., 2003), and facilitate mRNA export from the nucleus (York et al., 1999).

Altered MI levels have been observed in the brains of patients of Alzheimer’s disease, those suffering from mental disorders, and suicide and stroke victims (McLaurin et al., 1998; Macri et al., 2006). High fetal inositol concentrations in the cerebrospinal fluid have been attributed to the pathogenesis of Down’s syndrome (Acevedo et al., 1997). Administration of MI has been found to be therapeutic for obsessive-compulsive disorder and panic disorder (Seelan et al., 2009). Lower frontal cortex MI is linked to the pathophysiology of depression and concomitant sleep symptoms (Urrila et al., 2017).

MI deficiency causes high accumulation of triacylglycerol, cholesterol, and non-esterified lipids in the mammalian liver. A minimum threshold level of free MI deters the formation of fatty liver (Burton and Wells, 1974; Hayashi et al., 1974a; Hayashi et al., 1974b). Hence, the metabolic understanding of MI status in any biological organ or system is primarily dependent on MIPS activity and its regulation.

Chemistry

Chemically inositols are isomers of hexahydroxy-cyclohexanes. Among the nine possible geometrical isomers of inositol, seven are optically inactive or “meso,” and the remaining two form a chiral pair. The planar structures of the different isomers of this compound are presented in Figure 1 . The molecule of MI has one axial and five equatorial hydroxyl groups. The axial hydroxyl group at position 2 is most stable to hydrolysis.

Figure 1.

Figure 1

Open in a new tab

The planar structure of nine possible stereoisomers of inositol.

L-myo-inositol-1-phosphate synthase (MIPS) catalyzes the first step in the biosynthesis of all myo-inositol-containing compounds (Seelan et al., 2009). It converts glucose-6-phosphate to myo-inositol-1-phosphate (MIP). The phosphate moiety in MIP is subsequently removed by myo-inositol-1-phosphatase (IMPase) to produce free MI (Majumder and Biswas, 2006).

In addition, this compound could also be produced by cyclic synthesis (Agranoff et al., 1958; Paulus and Kennedy, 1960) and the hydrolysis of phosphatidylinositol. Although MIP is the intermediate common to both pathways, two different forms of compound are produced, the L-form by the synthetic pathway and the D-form by the cyclic pathway (Parthasarathy and Eisenberg, 1986). However, both the isomers are catalyzed by IMPase (Eisesnberg, 1967), which produces MI.

Myo-Inositol in Disease and Medicine

Elevated MI levels have been observed in Alzheimer’s disease, gliomatosis cerebri, diabetes mellitus, systemic lupus erythematosus, multiple sclerosis, etc. Further, decreased brain levels of MI were observed in chronic hepatic and hypoxic encephalopathy, stroke, acute thyrotoxic Graves’ disease, toxoplasmosis, cryptococcosis, and lymphoma (Haris et al., 2011). In the following section, important diseases that are influenced by MI and its derivatives ( Table 1 ) have been reviewed.

Table 1.

Pharmacological effects of myo-inositol and its derivatives against different disease symptoms.

Effective inositol derivative Affected tissue/organ Disease/symptom Reference
MI Intestine (gerbil) Lypodystrophy Hegsted et al., 1973
MI Heart (rat) Left ventricular stiffness Regan et al., 1973
MI Liver (rat) Fatty liver disease Burton and Wells, 1974; Hayashi et al., 1974a; Hayashi et al., 1974b
MI Brain (human) Affective disorder Barkai et al., 1978
MI Lung (mouse) Tumor Wattenberg, 1996
MI Brain (human) Suicidal tendency Shimon et al., 1997
MI Liver (mouse) Cancer Nishino et al., 1999
MI Lung (human) Tumor Jyonouchi et al., 1999
IP6 Heart (rat) Calcification of vessels Grases et al., 2000
DCI-IPGs Ovary (human) PCOS Sabuncu et al., 2001
DCI Diabetic human Endothelial dysfunction Larner, 2002
DCI Diabetic human Endothelial dysfunction, metabolic syndrome, erectile dysfunction Nacimento et al., 2006
PIP3 Nerve tissue, thyroid gland, colon, lung, prostate gland, skin (human) Cancer Luo et al., 2003; Osaki et al., 2004; Yuan and Cantley, 2008
IP6 + MI Colon, breast, lung (human) Cancer Vucenic and Shamsuddin, 2003; Vucenic and Shamsuddin, 2006
MI Brain (human) Depression Coupland et al., 2005; Shirayama et al., 2017
MI Fetal brain (human) Down’s syndrome Seelan et al., 2009
PIP2 Ovary, breast, lung, colon, stomach (human) Cancer Engelman et al., 2006; Yuan and Cantley, 2008
MI Brain (human) Bipolar disorder Saltiel et al., 2007
MI Brain (human) Mild cognitive disorder Berman et al., 2008; Voronov et al., 2008
MI Brian (human) Alzheimer’s disease Siger et al., 2009
DCI/MI ratio Diabetic human Insulin resistance Larner et al., 2010
MI Lung (mouse) Tumor Kassie et al., 2010
IP6 + MI Breast (human) Cancer Bacic et al., 2010
IP6 Prostate gland (human) Cancer Gu et al., 2010
DCI Ovary (human) Poor oocyte quality Carlomagno et al., 2011; Isabella and Raffone, 2012; Simi et al., 2017
PIP2 Brain (human) Schizophrenia Lo Vasco et al., 2012
MI + DCI Ovary (human) PCOS Minozzi et al., 2013
Open in a new tab

DCI, D-chiro-inositol; ED, endothelial dysfunction; IP6, Myo-inositol hexakisphosphate/phytic acid; IPG, inositol phosphoglycan; MI, Myo-inositol; PIP2, phosphatidylinositol inositol 4,5-bisphosphate; PIP3, phosphatidyl inositol 3,4,5-trisphosphate.

Dyslipidemia and Cardiac Diseases

Ever since it was known that MI deprivation in diet resulted in fatty liver condition in rats (Burton and Wells, 1974, Hayashi et al., 1974a; Hayashi et al., 1974b), the interest regarding its therapeutic value developed. MI also reduced the accumulation of hepatic triglyceride in the liver (McCrea and Camilli, 2009). Treatment with MI assisted in the removal of cholesterol from the myocardium, resulting in the decrease in lipid buildup in the heart that improved heart function. The reduction in myocardial lipid content ultimately resulted in the decrease in left ventricular stiffness (Regan et al., 1973).

A family of proteins called myotubularins which are actually inositol-3-phosphatases that dephosphorylate PI3P and PI(3,5)P2 are implicated in cardiomyopathy. It has been found that mutations in the genes coding for the aforementioned proteins caused cardiomyopathy (McCrea and Camilli, 2009). Nebivolol, a beta-blocker drug, induces vasorelaxation through activation of inositol phosphate metabolism (Parenti et al., 2000). Calcification of heart vessels is an undesirable attribute of cardiovascular disease (CVD), and IP6 acts as a crystallization inhibitor of calcium salts in vitro, reducing the calcification of coronary arteries (Grases et al., 2000).

Diabetic Complications

It is a known fact that, in diabetic animals, there is limited metabolism of fructose in the nerve system leading to the accumulation of sorbitol and fructose, which is responsible for peripheral neuropathy (Grabby, 1973). This causes a decrease in the motor nerve conduction velocity as well as in the MI concentration of the sciatic nerve at the onset of diabetes (Greene et al., 1975). These anomalies could be prevented by the exogenous administration of MI (Palmano et al., 1977).

Endothelial dysfunction (ED) caused by hyperglycemia and hyperlipidemia is an early feature of diabetes (Nacimento et al., 2006). Inositol phosphoglycans (IPGs) are generated rapidly in response to insulin and have an insulin-like effect in vivo and in vitro (Huang et al., 1999). In human urine, the level of chiro-inositol is decreased, while the MI content increased in diabetic subjects. The decreased urinary chiro-inositol is inversely correlated to insulin resistance. Administration of D-chiro-inositol (DCI) in diabetic humans effectively decreased hyperglycemia and hypertriglyceridemia (Larner, 2002).

In type 2 diabetic subjects, the higher levels of MI and the lower levels of DCI are referred to as inositol imbalance. Chiro-inositol deficiency and imbalance with myo-inositol are directly related to insulin resistance (Larner et al., 2010).

Cancer

Carcinogenesis in various organs may be inhibited by MI. Significant suppression of liver carcinogenesis by the oral administration of MI has been observed in mice (Nishino et al., 1999). Benzo[a]pyrene (B[a]P), a carcinogen derived from tobacco, causes lung tumor in rodents through its metabolite, anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (B[a]PDE). Interestingly, the same metabolite inhibits the differentiation of small airway epithelial cells (SAE) in humans. MI protects SAE cells against such inhibitory effects (Jyonouchi et al., 1999). When MI was added to dexamethasone (another compound that prevents pulmonary neoplasia), an additive effect was observed on the inhibition of lung carcinogenesis (Wattenberg, 1999). Administration of MI decreases the multiplicity and size of surface tumors. It also decreases the size of adenocarcinoma, and therefore, it may be utilized for the chemoprevention of early pulmonary lesions (Kassie et al., 2010).

Striking anticancer effects of IP6 and inositol have been demonstrated in experimental models (Vucenic and Shamsuddin, 2003). In colon, breast, and metastatic lung cancer models, the effect of the combination of IP6 and MI was significantly better than by either of the two acting alone (Vucenic and Shamsuddin, 2003, 2006). IP6 also inhibits prostate cancer (Pca) cell proliferation and stimulates their apoptotic death. IP6 inhibits constitutive and growth factor-induced signaling pathways, which eventually leads to the inhibition of growth and the induction of apoptotic death of Pca cells (Gu et al., 2010).

Mental Afflictions and Cognitive Diseases

Evidences suggest that the MI level in brain is associated with changes in mood state. The MI levels in the frontal coretex of suicide victims and those suffering from bipolar disorder were 23 and 30% lower, respectively, than the normal levels (Shimon et al., 1997). Patients of major depressive disorder have shown significantly lower MI/creatine ratios. The low levels of MI in the prefronatal/anterior cingulate cortex in major depressive disorder patients may be a consequence of altered glial metabolism (Coupland et al., 2005). Abnormal level of MI along with glutamate and glutamine was found in the brains of major depressive patients (Shirayama et al., 2017).

Administration of lithium causes a lowering of MI in the critical areas of the brain, and the effect is therapeutic. Lithium reduces MI level in the right frontal lobe in the brains of patients with manic depression. On the other hand, valproic acid (VPA) decreases the intercellular concentrations of inositol by inhibiting the key enzyme of MI biosynthesis, MIPS, in the human brain (Saltiel et al., 2004). Derivatives of VPA, valnoctamide (VCD), and valrocemide (VGD) are potent anticonvulsant drugs (Loscher and Nau, 1985; Anderson et al., 1992). The fact that 1mM VCD and VGD drastically inhibited human brain MIPS activity supports the view that these derivatives act as potential mood stabilizers (Saltiel et al., 2007).

The extra chromosome 21 in Down’s syndrome (DS), which leads to dementia later in life, is phenotypically similar to Alzheimer’s disease (AD). The presence of approximately 50% higher level of MI in DS patients suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo-inositol cotransporter gene is located. Still, higher levels of MI in older adults with DS are similar to that symptomatic of AD (Huang et al., 1999).

Synaptojanin-1 is a polyphosphosphoinositide phosphatase found in the neurons may have a role in the early onset of AD associated with DS. This enzyme is responsible for maximum of the PIP2 phosphatase activity in the brain and plays a critical role in synaptic transmission (Di Paolo and DeCamilli, 2006). The AD peptide Aβ42 stimulates PIP2 cleavage and leads to abnormal PIP2 metabolism in AD (Berman et al., 2008). The genes encoding synaptojanin-1 as well as the Aβ42 precursor is located in chromosome 21, the triplication of which is responsible for DS (McCrea and Camilli, 2009). In DS patients, the level of synaptojanin-1 is increased, and the corresponding level of PIP2 is decreased.

People with mild cognitive disorder (MCI) have higher risk of conversion to AD. In MCI, increased manifestation of MI occurs in the parietal white matter (WM), while in AD, the elevation of MI was found throughout the WM (Zhu et al., 2006). Therefore, MI level in MCI may be regarded as an early indicator of AD (Siger et al., 2009).

Abnormalities in signal transduction play a role in the development of mood disorders. Activated PI-PLC cleaves PIP2 into IP3 and DAG, both of which are crucial molecules for signal transduction (Suh et al., 2008). Different PI-PLC enzymes are tissue-specific, and the different expression of some isoforms was described in pathological conditions (Lo Vasco et al., 2013). A role of PI-PLC β1 in mood disorders has been suggested (Lo Vasco et al., 2012), and this hypothesis is in sync with the data obtained from schizophrenia models (Mc Omish et al., 2008). PI-PLC β1 was also suggested to represent a molecular convergence point of several neurotransmitter pathways implicated in schizophrenia (Choi et al., 1989; Kim et al., 1997).

Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is the most common form of the endocrine metabolic diseases affecting 6–10% of women of reproductive age (Diamanti-Kandarakis et al., 1999). Insulin resistance (IR) and compensatory hyperinsulinemia play an integral role in the pathogenesis of this syndrome (Nestler, 1997). IR places these women at an increased risk of the development of cancer, hypertension, dyslipidemia, type 2 diabetes, and CVDs (Burghen et al., 1980). It is known that some functions of insulin require low molecular weight IPGs (Dona et al., 2012) and also that a deficiency in DCI containing IPGs and/or altered DCI metabolism may contribute to IR.

Besides IR, hyperandrogenism is another feature of PCOS. This hyperandrogenism is related to alteration of steroidogenesis in ovary and adrenal glands (Reyes-Munoz et al., 2018). Androgens act synergistically with follicle stimulating hormone (FSH) and modify steroidogenesis enzymes (Lenie and Smitz, 2009) which is also related to IR.

In women with PCOS, administration of DCI improves clinical features of the syndrome (Baillargeon et al., 2010). Moreover, combined therapy of MI and DCI improves the metabolic profile of obese PCOS patients, reducing the risk of CVD (Minozzi et al., 2013). MI may be incorporated into membrane phosphatidylinositols, or it may constitute IPGs in response to insulin. After its release, the IPGs interact with tissues involved in insulin action, thus potentiating the effects of insulin (Cheang et al., 2008). PCOS patients also exhibit an increased DCI/MI ratio (i.e., overproduction of DCI). This in turn leads to MI deficiency in the ovary. A balance between the two inositols is associated with IR and sensitivity (Heimark et al., 2013).

Epilepsy

In case of patients with temporal lobe epilepsy (TLE), MI level increases in the areas of seizure focus (temporal lobe) and its concentration decrease in the areas of seizure spread i.e., frontal lobe (Wellard et al., 2003). In the temporal lobe, the increased MI has been reported as a consequence of induction of Na+/MI cotransporter1 (SMIT1) after seizure activity in the area of seizure focus (Nonaka et al., 1999). The decreased MI in the frontal lobe reflects the osmolyte changes due to secondary effect of seizures. MI is transported from extracellular fluid into the cell through SMIT1. Overexpression of SMIT1 as well as MI supplementation increases intracellular phosphoinositide level and thereby alters phosphoinositide modulated ion channels suggesting the role of SMIT1 in signaling (Dai et al., 2016).

In experimental rats, MI treatment significantly reduces the severity of status epilepticus induced by kianic acid. The treatment reduced both the frequency and duration of spontaneous recurrent seizures, the main character of epilepsy. In addition, MI had significant effects on SMIT1 and leucine rich repeat-containing 8A, a component of volume regulated anionic channel (Tsverava et al., 2019).

The IMPA2 gene located at human chromosome 18p 11.2 is responsible for febrile seizure (FS). IMPA2 codes for myo-inositol monophosphatase 2 that converts inositol monophosphate to MI and plays important role in phosphatidylinositol signaling pathway (Nakayama et al., 2004).

Discussion

It is a foregone conclusion that MI and its derivatives exert various metabolic actions generating therapeutic outcomes. The activities are due to reduction in ROS generation, direct superoxide scavenging, protection of NO signaling, etc. For example, DCI may be considered a therapeutic agent against metabolic syndrome, endothelial dysfunction, and erectile dysfunction in diabetes patients (Nacimento et al., 2006), and MI may act as alternative of metformin, the most popular oral antidiabetic drug, because it interacts directly with insulin target tissues; however, it does not show the side effects of the drug (Dona et al., 2012). The insulin like action of MI and DCI is due to the production of inositol glycan secondary messengers. These inositol glycans may modulate cell signaling, and in addition, inositols are incorporated in cell membrane phospholipids (Lagana et al., 2018).

Depression and schizophrenia are severe psychiatric diseases that affect millions of individuals worldwide, consequently increasing global suicide levels (Ren, 2019). MI and its derivatives may be a very important adjunct therapy in such cases. The most important role of MI is found in the treatment of bipolar disorder. More often than not, lithium is the first line of defense in such cases. However, lithium treatment often leads to psoriasis and depression. In such cases, MI may act as a preferable alternative since it is effective in mood stabilization as well as in the treatment of psoriasis (Kontoangelos et al., 2010).

The importance of inositol in cancer lies in the fact that inositol-3-phosphatase is a potent tumor suppressor, and its mutation leads to many types of cancers (Luo et al., 2003; Osaki et al., 2004; Yuan and Cantley, 2008). On the other hand, activating mutations in PI3-kinases have been reported in ovarian, breast, lung, colon, and gastric cancers (Engelman et al., 2006; Yuan and Cantley, 2008). In addition, in breast cancer patients, IP6 and MI may be a valuable adjunctive therapy. They also help in ameliorating the side effects and improving the quality of life (Bacic et al., 2010).

In oligoasthenospermia (OA), reduction in the number and motility of spermatozoa takes place. MI plays a crucial role in the osmoregulation of seminal fluid, thereby improving sperm motility. The antioxidant effect of MI also plays important role in the production and regulation of spermatozoa. Therefore, MI could be used in OA patients undergoing an in vitro fertilization cycle (Gulino et al., 2016). ROS affects not only the morphology and motility of spermatozoa but may also damage mitochondrial membrane potential (MMP) which in turn increases ROS production. MI may improve the sperm mitochondrial function, thereby improving sperm parameters in OA patients (Condorelli et al., 2017).

In women with PCOS, the combined therapy of MI plus DCI is able to influence the metabolism leading to improved lipid profile. However, in these patients, enhanced epimerization of MI to DCI takes place in the ovary, leading to excess DCI and less MI (Isabella and Raffone, 2012). This MI depletion eventually leads to poor oocyte quality (Carlomagno et al., 2011). MI supplementation may salvage the situation by improving oocyte quality (Simi et al., 2017).

The spurt of research on inositol biochemistry started from the 1960s with different groups taking the lead on various aspects of the work (Ballou and Pizer, 1960; Shaktin and Tatum, 1961; Nagai and Funahashi, 1962, Plouvier, 1963; Michell and Hawthorne, 1965; Charalampous and Chen, 1966; Eisesnberg, 1967; Sherman et al., 1968; Dittmer and Douglas, 1969). Now, the molecules have again come into focus primarily due to the continued increase in lifestyle diseases and the long quest for effective and non-toxic cure for the same. ROS reduction may be one of the strategies of MI derivatives for its therapeutic functions. In diabetes and heart ailments, ROS generation by NADPH oxidase action and mitochondrial disruption could be inhibited by DCI (Vendrov et al., 2015). IP3 signaling may be another mechanism by which MI derivatives influence cellular functions. IP3 is responsible for Ca2+ release from the ER which raises the cytosolic Ca2+, and this in turn activates many enzymes and proteins. Indeed, defective IP3 receptors have been found responsible for many neurodegenerative disorders (Egorova and Bezprozvanny, 2018). Thus, MI and its derivatives may well play important roles not only to ameliorate cancers and psychotic diseases but also in many lifestyle diseases like obesity, diabetes, CVD, etc. This report tried to highlight these critical areas.

Author Contributions

DC conceptualized the article, prepared the manuscript and did the editing.

Funding

Supported by National Mission on Himalayan Studies (NMHS) grant of the Government of India (Ref. No. NMHS/MG-2016/005).

Conflict of Interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgment

The author acknowledges the intellectual help provided by Prof. Shanti Swarup Sharma, Department of Botany, Sikkim University. The author is thankful to Ms. Tushita Karuna Chhetri for editing the language of the manuscript and Dr. Sachina Yonzone, Department of Botany, Darjeeling Government College is acknowledged for the assistance she has provided. The author is indebted to the referees for their constructive suggestions.

References

  1. Acevedo L. D., Holloway H. W., Rapoport S. I., Shetty H. U. (1997). Application of stable isotope tracer combined with mass spectrometric detection for studying myo-inositol uptake by cultured neurons from fetal mouse: effect of trisomy 16. J. Mass Spectrom. 32, 395–400. [DOI] [PubMed] [Google Scholar]
  2. Agranoff B. W., Bradley R. M., Brady R. O. (1958). The enzymatic synthesis of inositol phosphatide. J. Biol. Chem. 233, 1077–1083. [PubMed] [Google Scholar]
  3. Anderson G. D., Acheampong A. A., Wilensky A. J., Levy R. H. (1992). Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 33, 736–742. 10.1111/j.1528-1157.1992.tb02355.x [DOI] [PubMed] [Google Scholar]
  4. Bacic I., Druzijanic N., Karlo R., Skific I., Jagic S. (2010). Efficacy of IP6 + inositol treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J. Exp. Clic. Res. 29, 1–5. 10.1186/1756-9966-29-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baillargeon J.-P., Iuorno M. J., Apridonidze T., Nestler J. E. (2010). Uncoupling Between insulin and release of a D-Chiro-inositol–containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 8, 127–136. 10.1089/met.2009.0052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ballou C. E., Pizer L. I. (1960). The absolute configuration of the myo-inositol 1-phosphate and a confirmation of the bornesitol configurations. J. Am. Chem. Soc. 82, 3333–3335. 10.1021/ja01498a026 [DOI] [Google Scholar]
  7. Barkai A. I., Dunner D L., Gross H. A., Mayo P., Fieve R. R. (1978). Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol. Psychiatry 13, 65–72 [PubMed] [Google Scholar]
  8. Berman D. E., Dall’Armi C., Voronov S. V., et al. (2008). Oligomeric amyloid-beta peptide disrupts phophatidylinositol-4,5 bisphosphate metabolism. Nat. Neurosci. 11, 547–554. 10.1038/nn.2100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Berridge M. J. (2009). Inositol trisphosphate and calcium signalling mechanisms. Biochim. Biophys. Acta 1793, 933–940. 10.1016/j.bbamcr.2008.10.005 [DOI] [PubMed] [Google Scholar]
  10. Burghen G. A., Givens J. R., Kitabchi A. E. (1980). Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50, 113–116. 10.1210/jcem-50-1-113 [DOI] [PubMed] [Google Scholar]
  11. Burton L. E., Wells W. W. (1974). Studies on the developmental pattern of the enzymes converting glucose-6-phosphate to myo-inositol in the rat. Develop. Biol. 37, 35–42. 10.1016/0012-1606(74)90167-5 [DOI] [PubMed] [Google Scholar]
  12. Carlomagno G., Unfer V., Roseff S. (2011). The D-chiro-inositol paradox in the ovary. Fertil. Steril. 95, 2515–2516. 10.1016/j.fertnstert.2011.05.027 [DOI] [PubMed] [Google Scholar]
  13. Charalampous F., Chen I. W. (1966). Inositol-1-phosphate synthase and inositol 1-phosphatase from yeast. Methods Enzymol. 9, 698–704. 10.1016/0076-6879(66)09141-9 [DOI] [Google Scholar]
  14. Cheang K. I., Baillargeon J. P., Essah P. A., Ostlund R. E., Apridonize T., Islam L., et al. (2008). Insulin-stimulated release of D-chiro-inositol containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism: Clin. Expt. 10, 1390–1397. 10.1016/j.metabol.2008.05.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Choi W. C., Grefen C. R., Suh P. G., Rhee S. G. (1989). Immunohistochemical localization of a brain isozyme of phospholipase C (PLC III) in astroglia in rat brain. Brain Res. 499, 193–197. 10.1016/0006-8993(89)91153-0 [DOI] [PubMed] [Google Scholar]
  16. Condorelli R. A., La-Vignera S., Mongioi L. M., Vitale S. G., Cimino L., Calogero A. E. (2017). Myo-inositol as a male fertility molecule: Speed them up. Eur. Rev. Med. Phammacol. Sci. 21, 30–35. [PubMed] [Google Scholar]
  17. Coupland N. J., Ogilivie C. J., Hegadoren K. M., Seres P., Hanstock C. C., Allen P. S. (2005). Decreased prefrontal myo-inositol in major depressive disorder. Biol. Psychiatry 57, 1526–1534. 10.1016/j.biopsych.2005.02.027 [DOI] [PubMed] [Google Scholar]
  18. Dai G., Yu H., Kruse M., Traynor-Kaplan A., Hillea B. (2016). Osmoregulatory inositol transporter SMIT1 modulates electrical activity by adjusting PI(4,5)P2 levels. Proc. Natl. Acad. Sci. U. S. A. 113, E3290–E3299. 10.1073/pnas.1606348113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Di Paolo G., DeCamilli P. (2006). Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651–657. 10.1038/nature05185 [DOI] [PubMed] [Google Scholar]
  20. Diamanti-Kandarakis E., Kouli C. R., Bergiele A. T., Filandra F. A., Tsianateli T. C., Spina G. G., et al. (1999). A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clinic. Endocrin. Metabol. 84, 4006–4011. 10.1210/jcem.84.11.6148 [DOI] [PubMed] [Google Scholar]
  21. Dittmer J. C., Douglas M. G. (1969). Quantitative determination of phosphoinositides. Ann. N. Y. Acad. Sci. 165, 515–525. 10.1111/j.1749-6632.1970.tb55933.x [DOI] [PubMed] [Google Scholar]
  22. Dona G., Sabbadin C., Fiore C., Bragadin M., Giorgino F. L., Ragazzi E., et al. (2012). Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol. 166, 703–710. 10.1530/EJE-11-0840 [DOI] [PubMed] [Google Scholar]
  23. Egorova P. A., Bezprozvanny I. B. (2018). Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders. FEBS Journal 285, 3547–3565. 10.1111/febs.14366 [DOI] [PubMed] [Google Scholar]
  24. Eisesnberg F. Jr. (1967). D-myo-Inositol-1-phosphate as product of cyclization glucose-6-phosphate and substrate for a specific phosphatase in rat testis. J. Biol. Chem. 242, 1375–1382. [PubMed] [Google Scholar]
  25. Engelman J. A., Luo J., Cantley L. C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606–619. 10.1038/nrg1879 [DOI] [PubMed] [Google Scholar]
  26. Grabby K. H. (1973). The sorbitol pathway and the complications of diabetes. N. Engl. J. Med. 288, 831–836. 10.1056/NEJM197304192881609 [DOI] [PubMed] [Google Scholar]
  27. Grases F., Ramis M., Costa-Bouza A. (2000). Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization: comparison with the action of othetr phosphates. Urol. Res. 28, 136–140. 10.1007/s002400050152 [DOI] [PubMed] [Google Scholar]
  28. Greene D. A., De P. V., Jesus, Winegrad A. I. (1975). Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J. Clin. Invest. 55 (6), 1326–1336. 10.1172/JCI108052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Gu M., Raina K., Agarwal C., Agarwal R. (2010). Inositol hexaphosphate downregulates both constitutive and ligand-induced mitogenic and cell survival signalling and causes capsase mediated apoptotic death of human prostrate carcinoma PC-3 cells. Mol. Carcinog. 49, 1–12. 10.1002/mc.20560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gulino F. A., Leonardi E., Marilli I., Musmesi G., Vitale S. G., Leanza V., et al. (2016). Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: in vivo study. Gynecol. Endocrinol. 32, 65–68. 10.3109/09513590.2015.1080680 [DOI] [PubMed] [Google Scholar]
  31. Haris M., Cai K., Singh A., Hariharan H., Reddy R. (2011). In-vivo mapping of brain myo-inositol. Neuroimage 54, 2079–2085. 10.1016/j.neuroimage.2010.10.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hayashi E., Maeda T., Tomita T. (1974. a). The effect of myo-inositol deficiency on lipid metabolism in rats. I. The alteration of lipid metabolism in myo-inositol deficient rats. Biochim. Biophys. Acta 360, 134–145. 10.1016/0005-2760(74)90163-5 [DOI] [PubMed] [Google Scholar]
  33. Hayashi E., Maeda T., Tomita T. (1974. b). The effect of myo-inositol deficiency on lipid metabolism in rats. II. The effect of triacylglycerol accumulation in the liver of myo-inositol deficient rats. Biochim. Biophys. Acta 360, 146–155. 10.1016/0005-2760(74)90164-7 [DOI] [PubMed] [Google Scholar]
  34. Hegsted D. M., Hayes K. C., Gallagher A., Hanford H. (1973). Inositol deficiency: an intestinal lipodystrophy in the gerbil. J. Nutr. 103, 302–307. 10.1093/jn/103.2.302 [DOI] [PubMed] [Google Scholar]
  35. Heimark D., McAllister J., Larner J. (2013). Decreased myo-inositol to chiro-inositol (m/c) ratios and increased m/c epimerase activity in pcos theca cells demonstrate increased insulin sensitivity compared to controls. Endocr. J. 10.1507/endocrj.EJ13-0423 [DOI] [PubMed]
  36. Huang W., Alexander G. E., Daly E. M., Shetty H. U., Krasuski J. S., Rapoport S. I., et al. (1999). High brain myo-inositol levels in the predementia phase of Alzheimer’s disease in adults with Down’s syndrome: a 1H MRS study. Am. J. Psychiatry 156, 1879–1886. 10.1176/ajp.156.12.1879 [DOI] [PubMed] [Google Scholar]
  37. Isabella R., Raffone E. (2012). Does ovary need D-chiro-inositol? J. Ovarian Res. 5 (14), 1–5. 10.1186/1757-2215-5-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Jyonouchi H., Sun S., Ijima K., Wang M., Hecht S. S. (1999). Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Carcinogenesis 20, 139–145. 10.1093/carcin/20.1.139 [DOI] [PubMed] [Google Scholar]
  39. Kassie F., Kalscheuer S., Matise I., Ma L., Melkamu T., Upadhayaya P., et al. (2010). Inhibition of vinyl carbamate induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis 31, 239–245. 10.1093/carcin/bgp174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kim D., Jun K. S., Lee S. B., Kang N. G., Min D. S., Kim Y. H., et al. (1997). Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature 389, 290–293. 10.1038/38508 [DOI] [PubMed] [Google Scholar]
  41. Kontoangelos K., Vaidakis N., Zervas I., Thomadaki O., Smaragda C., Stavrianeas N. G., et al. (2010). Administration of inositol to a patient with bipolar disorder and psoriasis: a case report. Cases J. 3, 1–3. 10.1186/1757-1626-3-69 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lagana A. S., Garzon S., Casarin J., Franchi M., Ghezzi F. (2018). Inositol in polysystic ovary syndrome: restoring fertility through a pathophysiology based approach. Trends Endocr. Metabol. 29, 768–780. 10.1016/j.tem.2018.09.001 [DOI] [PubMed] [Google Scholar]
  43. Larner J. (2002). D-chiro-inositol – Its functional role in insulin action and its deficit in insulin resistance. Int. J. Exp. Diabetes Res. 3, 47–60. 10.1080/15604280212528 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Larner J., Brautigan D. L., Thorner M. O. (2010). D-chiro inositol glycans in insulin signaling and insulin resistance. Mol. Med. 16, 543–551. 10.2119/molmed.2010.00107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lenie S., Smitz J. (2009). Functional AR signalling is evident in an in vitro mouse follicle culture bioassay that encompasses the most stages of folliculogenesis. Biol. Reprod. 80, 685–695. 10.1095/biolreprod.107.067280 [DOI] [PubMed] [Google Scholar]
  46. Lo Vasco V. R., Cardinale G., Polonia P. (2012). Deletion of PI-PLC β1 gene in schizophrenia affected patients. J. Cell Mol. Med. 16, 844–851. 10.1111/j.1582-4934.2011.01363.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Lo Vasco V. R., Longo L., Polonia P. (2013). Phosphoinositide –specific phospholipase C beta1 gene deletion in bipolar disorder affeted patients. J. Cell Commun. Signal. 7: 25–29. 10.1007/s12079-012-0182-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Loscher W., Nau H. (1985). Pharmacological evaluation of various metabolites and analogs of valproic acid: anticonvulsant and toxic potencies in mice. Neuropharmacology 24, 427–435. 10.1016/0028-3908(85)90028-0 [DOI] [PubMed] [Google Scholar]
  49. Luo J., Manning B. D., Cantley L. C. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257–262. 10.1016/S1535-6108(03)00248-4 [DOI] [PubMed] [Google Scholar]
  50. Macri M. A., D’Alessandro N., Di Giulio C., Di Iorio P., Di Luzio S., Giuliani P., et al. (2006). Regional changes in the metabolite profile after long-term hypoxia-ischemia in brains of young and aged rats: a quantitative proton MRS study. Neurobiol. Aging 27, 98–104. 10.1016/j.neurobiolaging.2005.01.007 [DOI] [PubMed] [Google Scholar]
  51. Majumdar A. L., Johnson M. D., Henry S. A. (1997). 1L–myo-Inositol–1-phosphate synthase. Biochim. Biophys. Acta 1348, 245–256. 10.1016/S0005-2760(97)00122-7 [DOI] [PubMed] [Google Scholar]
  52. Majumder A. L., Biswas B. B. (2006). “Biology of inositols and phosphoinositides,” in subcellular biochemistry (USA: Springer; ). 10.1007/0-387-27600-9 [DOI] [Google Scholar]
  53. Mc Omish C. E., Burrows E. L., Howard M., Hannan A. J. (2008). PI-PLC β1 knockout mice as a model of disrupted cortical development and plasticity: behavioral endophenotypes and dysregulation of RGS4 gene expression. Hippocampus 18, 824–834. 10.1002/hipo.20443 [DOI] [PubMed] [Google Scholar]
  54. McCrea H. J., Camilli P. D. (2009). Mutations in phosphoinositides metabolizing enzymes and human disease. Physiology 24, 8–16. 10.1152/physiol.00035.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. McLaurin J., Franklin T., Chakrabartty A., Fraser P. E. (1998). Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J. Mol. Biol. 278, 183–194. 10.1006/jmbi.1998.1677 [DOI] [PubMed] [Google Scholar]
  56. Michell R. H., Hawthorne J. N. (1965). The site of diphosphoinositide synthesis in rat liver. Biochem. Biophys. Res. Commun. 21, 333–338. 10.1016/0006-291X(65)90198-1 [DOI] [PubMed] [Google Scholar]
  57. Minozzi M., Nordio M., Pajalich R. (2013). The combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur. Rev. Med. Pharmacol. Sci. 17, 537–540. 10.1155/2013/424163 [DOI] [PubMed] [Google Scholar]
  58. Nacimento N. R. F., Less L. M. A., Kewrntopf M. R., Sousa C. M., Alves R. S., Queiroz M. G. R., et al. (2006). Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and bt scavenging superoxide. PNAS 103, 218–223. 10.1073/pnas.0509779103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Nagai Y., Funahashi S. (1962). Phytase (myo-inositol hexaphosphate phosphohydrolase) from wheat bran. I. Purification and substrate specificity. Agri. Biol. Chem. 26, 794–803. 10.1080/00021369.1962.10858050 [DOI] [Google Scholar]
  60. Nakayama J., Yamamoto N., Hamano K., Iwasaki N., Ohta M., Nakahara S., et al. (2004). Linkage and association of febrile seizures to the IMPA2 gene on human chromosome 18. Neurology 63, 1803–1807. 10.1212/01.WNL.0000144499.34164.E0 [DOI] [PubMed] [Google Scholar]
  61. Nestler J. E. (1997). Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin. Reprod. Endocrin. 15, 111–122. 10.1055/s-2007-1016294 [DOI] [PubMed] [Google Scholar]
  62. Nishino H., Murakoshi M., Masuda M., Tokuda H., Satomi Y., Onozuka. M., et al. (1999). Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol. Anticancer Res. 19, 3663–3664. [PubMed] [Google Scholar]
  63. Nonaka M., Kohmura E., Yamashita T., Yamauchi A., Fujinaka T., Yoshimine T., et al. (1999). Kainic acid-induced seizure upregulates Na(+)/myo-inositol cotransporter mRNA in rat brain. Brain Res. Mol. Brain Res. 70, 179–186. 10.1016/S0169-328X(99)00127-8 [DOI] [PubMed] [Google Scholar]
  64. Odom A. R., Stahlberg A., Wente S. R., York J. D. (2000). A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science 287, 2026–2029. 10.1126/science.287.5460.2026 [DOI] [PubMed] [Google Scholar]
  65. Osaki M., Oshimura M., Ito H. (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667–676. 10.1023/B:APPT.0000045801.15585.dd [DOI] [PubMed] [Google Scholar]
  66. Palmano K. P., Whiting P. H., Hawthorne J. N. (1977). Free and lipid myo-inositol in tissues from rats with acute and less severe streptozotocin-induced diabetes. Biochem. J. 167, 229–235. 10.1042/bj1670229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Parenti A., Filippi S., Amerini S., Granger H. J., Fazzini A., Ledd F. (2000). Inositol phosphate metabolism and nitric oxide synthase activity in endothelial cells are involved in the vaso-relaxant activity of Nebivolol. J. Pharmacol. Exp. Ther. 299, 698–703. [PubMed] [Google Scholar]
  68. Parthasarathy R., Eisenberg F., Jr. (1986). The inositol phospholipids: a stereochemical view of biological activity. Biochem. J. 235, 313–322. 10.1042/bj2350313 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Paulus H., Kennedy E. P. (1960). The enzymatic synthesis of inositol monophosphatide. J. Biol. Chem. 235, 1303–1311. [PubMed] [Google Scholar]
  70. Plouvier V. (1963). “Distribution of aliphatic polyols and cyclitol,” in Chemical plant taxonomy. Ed. Swain T. (New York: Academic Press; ), 313–336. 10.1016/B978-0-12-395540-1.50015-4 [DOI] [Google Scholar]
  71. Regan T. J., Khan M. I., Jesrani M. U., Oldewurtel H. A., Ettinger P. O. (1973). “Alteration of myocardial function and metabolism in chronic diabetes mellitus,” in Recent advances in studies of cardiac structure and metabolism. Ed. Dhalla N. S. (Baltimore: University Park; ). [PubMed] [Google Scholar]
  72. Ren Q. (2019). Soluble epoxide hydrolase inhibitor: a novel potential therapeutic or prophylactic drug for psychiatric disorders. Front. Pharmacol. 10, 420. 10.3389/fphar.2019.00420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Reyes-Munoz E., Sathyapalan T., Rossetti P., Shah M., Long M., Buscema M., et al. (2018). Polycystic ovary syndrome: implication for drug metabolism on assisted reproductive techniques—a literature review. Adv. Ther. 35, 1805–1815. 10.1007/s12325-018-0810-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Sabuncu T., Vural H., Harma M., Harma M. (2001). Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin. Biochem. 34, 407–413. 10.1016/s0009-9120(01)00245-4 [DOI] [PubMed] [Google Scholar]
  75. Saiardi A., Bhandari R., Resnick A. C., Snowman A. M., Snyder S. H. (2004). Phosphorylation of proteins by inositol pyrophosphates. Science 306, 2101–2105. 10.1126/science.1103344 [DOI] [PubMed] [Google Scholar]
  76. Saltiel G., Shamir A., Shapiro J., Ding D., Dalton E., Bialer M., et al. (2004). Valproate decreases inositol biosynthesis. Biol. Psychiatry 56, 868–874. 10.1016/j.biopsych.2004.08.027 [DOI] [PubMed] [Google Scholar]
  77. Saltiel G., Shiley M., Kofman O., Belmaker R. H. (2007). Effect of valproate derivatives on human brain myo-inositol-1-phosphate synthase activity and amphetamine induced rearing. Pharm. Rep. 59, 402–407. [PubMed] [Google Scholar]
  78. Seelan R. S., Lakshmanan J., Manuel F., Casanova M. F., Parthasarathy R. N. (2009). Identification of myo-inositol-3-phosphate synthase isoforms: characterization, expression, and putative role of a 16-Kda γc isoform. J. Biol. Chem. 284, 9443–9457. 10.1074/jbc.M900206200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Shaktin A. J., Tatum E. L. (1961). The relationship of M-inositol to morphology of Neurospora crassa . Am. J. Bot. 48, 760–771. 10.1002/j.1537-2197.1961.tb11708.x [DOI] [Google Scholar]
  80. Shen X., Xiao H., Ranallo R., Wu W. H., Wu C. (2003). Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates. Science 299, 112–114. 10.1126/science.1078068 [DOI] [PubMed] [Google Scholar]
  81. Sherman W. R., Stewart M. A., Kurien M. M., Goodwin S. L. (1968). The measurement of myo-inositol, myo-inosose-2 and scyllo-inositol in mammalian tissues. Biochim. Biophys. Acta 158, 197–205. 10.1016/0304-4165(68)90131-1 [DOI] [PubMed] [Google Scholar]
  82. Shimon H., Agam G., Belmaker R. H., Hyde T. M., Kleinman J. E. (1997). Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am. J. Psychiatry 154, 1148–1150. 10.1176/ajp.154.8.1148 [DOI] [PubMed] [Google Scholar]
  83. Shirayama Y., Takahashi M., Osone F., Hara A., Okubo T. (2017). Myo-inositol, glutamate, and glutamine in the prefrontal cortex, hippocampus, and amygdala in major depression. Biol. Psychiatry: Cogn. Neurosci. Neuroimag. 2, 196–204. 10.1016/j.bpsc.2016.11.006 [DOI] [PubMed] [Google Scholar]
  84. Siger M., Schuff N., Zhu X., Miller B. L., Weiner M. W. (2009). Regional myo-inositol concentration in mild cognitive impairment using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis. Assoc. Disord. 23, 57–62. 10.1097/WAD.0b013e3181875434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Simi G., Genazzani A. R., Obino M. E. R., Papini F., Pinelli S., Cela V., et al. (2017). Inositol and in vitro fertilization with embryo transfer. Intl. J. Endocrinol. 5469409, 1–5. 10.1155/2017/5469409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Suh P. G., Park J., Manjoli L., Cocco L., Peak J. C., Katan M., et al. (2008). Multiple roles of phosphoinositides specific phospholipase C isozymes. BMB Reports 41, 415–434. 10.5483/BMBRep.2008.41.6.415 [DOI] [PubMed] [Google Scholar]
  87. Tsverava L., Kandashvili M., Margvelani G., Lortkipanidze T., Gamkrelidze G., Lepsveridze E., et al. (2019). Long-term effects of myo-inositol on behavioural seizures and biochemical changes evoked by kainic acid induced epileptogenesis. Biomed. Res. Int. 10.1155/2019/4518160 [DOI] [PMC free article] [PubMed]
  88. Urrila A. S., Hakkarainen A., Castaneda A., Paunio T., Marttunen M., Lundbom N. (2017). Frontal cortex Myo-inositol is associated with sleep and depression in adolescents: a proton magnetic resonance spectroscopy study. Neuropsychobiology 75, 21–31. 10.1159/000478861 [DOI] [PubMed] [Google Scholar]
  89. Vendrov A. E., Vendrov K. C., Smith A., Yuan J., et al. (2015). NOX4 NADPH oxidase-dependent mitochondrial oxidative stress in aging-associated cardiovascular disease. Antioxid. Redox Signal. 23, 1389–1409. 10.1089/ars.2014.6221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Voronov S. V., Frere S. G., Giovedi S., et al. (2008). Synaptojanin 1 linked phosphoinositide dyshomeostais and cognitive deficits in mouse models of Down’s Syndrome. Proc. Natl. Acad. Sci. USA. 105, 9415–9420. 10.1073/pnas.0803756105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Vucenic I., Shamsuddin A. M. (2003). Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to c linic. J. Nutr. 133, 3778S–3784S. 10.1093/jn/133.11.3778S [DOI] [PubMed] [Google Scholar]
  92. Vucenic I., Shamsuddin A. M. (2006). Protection against cancer by dietary IP6 and inositol. Nutr. Cancer 55, 109–125. 10.1207/s15327914nc5502_1 [DOI] [PubMed] [Google Scholar]
  93. Wattenberg L. W. (1996). Chemoprevention of cancer. Prev. Med. 25, 44–45. 10.1006/pmed.1996.0015 [DOI] [PubMed] [Google Scholar]
  94. Wattenberg L. W. (1999). Chemoprevention of pulmonary carcinogenesis by myo-inositol. Anticancer Res. 19, 3659–3661. [PubMed] [Google Scholar]
  95. Wellard R. M., Briellmann R. S., Prichard J. W., Syngeniotis A., Jackson G. D. (2003). Myoinositol abnormalities in temporal lobe epilepsy. Epilepsia 44, 815–821. 10.1046/j.1528-1157.2003.44102.x [DOI] [PubMed] [Google Scholar]
  96. York J. D., Odom A. R., Murphy R., Ives E. B., Wente S. R. (1999). A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285 96–100. 10.1126/science.285.5424.96 [DOI] [PubMed] [Google Scholar]
  97. Yuan T. L., Cantley L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497–5510. 10.1038/onc.2008.245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Zhu X., Schu N., Kornak J., et al. (2006). Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis. Assoc. Disord. 20, 77–85. 10.1097/01.wad.0000213809.12553.fc [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES